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The herpesviruses are a family of double-stranded DNA viruses that infect a wide variety
of organisms. Having co-evolved with their hosts over millennia, herpesviruses have devel-
oped a large repertoire of mechanisms to manipulate normal cellular processes for their
own beneﬁt. Consequently, studies on these viruses have made important contributions to
our understanding of fundamental biological processes. Here we describe recent research
on the human herpesviruses that has contributed to our understanding of, and interactions
between, viruses, autophagy, and the immune system.The ability of autophagy to degrade
proteins located within the nucleus, the site of herpesvirus latency and replication, is also
considered.
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INTRODUCTION
In mammalian cells three different autophagy pathways have been
shown to deliver cytoplasmic proteins or organelles into the lumen
of lysosomes for degradation. The ﬁrst pathway, microautophagy,
is a process in which the lysosomal membrane invaginates, captur-
ing portions of cytoplasm. Endosomal microautophagy has also
recently been described (Sahu et al., 2011). The second pathway,
chaperone-mediated autophagy (CMA), involves the transport
of proteins containing a speciﬁc motif into the lysosome via
the concerted actions of chaperone proteins and the lysosomal
membrane protein LAMP2a (Dice, 2007). The third pathway,
macroautophagy (hereafter referred to simply as autophagy) is
the best described of the three and can be divided into six
sequential steps: initiation, nucleation, elongation, closure, mat-
uration, and degradation. Each step is a highly regulated process
involving the coordinated action of numerous autophagy-related
(ATG) and other proteins. Initiation of autophagy occurs upon
activation of the ULK1 and UKL2 complexes following release
of their inhibition by the mTOR complex. Nucleation deﬁnes
the site for the autophagic membrane to begin to form in the
cytoplasm and depends on the oligomerization of Beclin-1 that
acts as a platform for recruitment of multiple other autophagy-
related proteins. Elongation of the autophagic membrane around
a portion of cytoplasm involves the recruitment of more pro-
teins and lipidation of the microtubule-associated protein light
chain 3 (LC3) by the E2-like enzyme ATG3. Closure of the mem-
brane completes the formation of the double membrane vacuole,
called an autophagosome, containing a portion of cytoplasm
within its lumen. The autophagosome then undergoes matura-
tion by fusing with lysosomes to form an autophagolysosome.
This process is again mediated by Beclin-1 as well as LC3 on
the autophagosome. Following maturation, the captured cyto-
plasmic contents are degraded by lysosomal proteases for reuse
by the cell.
Autophagy typically occurs continuously at a low level but
is increased in response to cellular stresses such as nutrient
deprivation in order to provide a supply of nutrients to aid cell
survival. In addition to this survival function, autophagy plays
other important roles that are the focus of this review.
Viruses are obligate intracellular parasites and therefore totally
dependentuponahost cell for replication. This dependencehas led
viruses to develop ways of harnessing normal cellular processes for
their ownpurposes. A diverse range of viruses has nowbeen shown
tomanipulate autophagy. Some viruses stimulate autophagy to aid
their replication. Infection with poliovirus induces the formation
of membranes resembling double-membrane autophagosomes
that contribute to virus production (Suhy et al., 2000; Jackson et al.,
2005). Rotavirus also stimulates the formation of autophagosome-
like structures with the virus replicating in close proximity to these
vesicles (Berkova et al., 2006). In contrast, autophagy poses a threat
for other viruses and a range of viral countermeasures have been
identiﬁed (Jordan and Randall, 2011). Autophagy inhibition has
been well characterized for members of the herpesvirus family. In
humans, eight herpesviruses have been identiﬁed that are divided
into three sub-families (alpha-, beta-, and gammaherpesvirinae).
These divisions were historically based on cellular tropism but are
now based on viral genome organization (Table 1). Viruses across
all sub-families are able to manipulate autophagy, employing a
range of different mechanisms. These mechanisms and the effects
on both viral replication and the host antiviral immune response
are described below.
HSV-1 INHIBITS AUTOPHAGY TO PREVENT
VIRAL DEGRADATION
Autophagy has been shown to play important roles in many
pathways of the innate immune system. These roles include mod-
ulating pathogen recognition receptors (Lee et al., 2007; Takeshita
et al., 2008), controlling the production of key innate cytokines
(Lee et al., 2007; Saitoh et al., 2008), and controlling phagocy-
tosis (Sanjuan et al., 2007; Zang et al., 2012). Autophagy can
directly contribute to innate immune control of viruses within
infected cells, a role identiﬁed in the ﬁrst study on Beclin-1
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Table 1 | Classification of the eight human herpesviruses.
Formal taxonomic Alternative common Viral sub-family
name name
Human herpesvirus 1 Herpes simplex virus 1 Alphaherpesvirinae
Human herpesvirus 2 Herpes simplex virus 2 Alphaherpesvirinae
Human herpesvirus 3 Varicella-zoster virus Alphaherpesvirinae
Human herpesvirus 4 Epstein–Barr virus Gammaherpesvirinae
Human herpesvirus 5 Human cytomegalovirus Betaherpesvirinae
Human herpesvirus 6 HHV-6 variant A or B Betaherpesvirinae
Human herpesvirus 7 HHV-7 Betaherpesvirinae
Human herpesvirus 8 Kaposi’s sarcoma- Gammaherpesvirinae
associated herpesvirus
(Liang et al., 1998). Overexpression of Beclin-1 in neurons pro-
tected mice against fatal infection with the neurotropic alphavirus
Sindbis (Note: Sindbis is a member of the Togaviridae family and
not a herpesvirus; Liang et al., 1998). This protection resulted
from the degradation of the Sindbis capsid protein by autophagy
(Orvedahl et al., 2010). A range of intracellular bacteria and viruses
are now known to be degraded by autophagy, a process termed
xenophagy (Rich et al., 2003; Gutierrez et al., 2004; Nakagawa et al.,
2004; Talloczy et al., 2006). The alphaherpesvirus herpes simplex
virus type 1 (HSV-1) provided the ﬁrst evidence of a pathogen
inhibiting autophagy to escape xenophagy. Within virus-infected
cells activation of cellular dsRNA-dependent protein kinase R
(PKR) inhibits host and viral protein translation and viral repli-
cation. HSV-1 encodes a protein, ICP34.5, which inhibits this
PKR-dependent antiviral activity (Chou et al., 1990). Talloczy et al.
(2002) demonstrated that ICP34.5 also prevents PKR-dependent
activation of autophagy in HSV-1-infected cells. Subsequent
research revealed that ICP34.5 binds the essential autophagy gene
Beclin-1 preventing the formation of autophagosomes (Orvedahl
et al., 2007). Deletion of the Beclin-1 binding domain from
ICP34.5 did not alter viral growth in vitro but could decrease
viral growth and neurovirulence in a mouse model. Note that this
decrease in neurovirulence could be due to a number of different
factors. For example, survival of infected cells might be increased
by the presence of a functional autophagy pathway. However, two
observations support a contribution from xenophagy in reducing
HSV-1 neurovirulence. First, HSV-1 virions can be observed in
vesicles that morphologically resemble autophagosomes (Smith
and de Harven, 1978; Talloczy et al., 2006). Second, biochemi-
cal studies show that inhibiting autophagy decreases the rate of
degradation of HSV-1 proteins (Talloczy et al., 2006).
HERPESVIRUSES DIFFER IN THEIR ABILITY TO
INHIBIT AUTOPHAGY
Other herpesviruses have also been shown to possess autophagy
inhibitory mechanisms. In cells infected with the betaherpesvirus
human cytomegalovirus (HCMV) autophagy is initially acti-
vated before being inhibited 24 h post infection (Chaumorcel
et al., 2008; McFarlane et al., 2011). HCMV-mediated autophagy
inhibition requires de novo viral protein synthesis and is mediated
by the viral protein TRS1 (Chaumorcel et al., 2012). Interestingly,
TRS1 appears to be a functional homolog of the HSV protein
ICP34.5, interacting with both PKR and Beclin-1. Like ICP34.5
it is the interaction between TRS1 and Beclin-1 that inhibits
autophagy.
The human gammaherpesvirus Kaposi’s sarcoma-associated
herpesvirus (KSHV) also inhibits autophagy by targeting Beclin-
1 but uses a different mechanism to do so. The cellular Bcl-2
protein inhibits apoptosis but can also inhibit autophagy by
binding Beclin-1(Pattingre et al., 2005). KSHV encodes a viral
homolog of Bcl-2, called orf16, that can similarly bind Beclin-1
and inhibit autophagy (Pattingre et al., 2005). It is not currently
knownwhether the two viral Bcl-2 homologs (BHRF1 andBALF1)
encoded by the other human gammaherpesvirus Epstein–Barr
virus (EBV) can similarly inhibit autophagy. However, it seems
likely that one or both of these viral proteins will do so given that
the viral Bcl-2 homolog encoded by another gammaherpesvirus,
in this case murine MHV68, inhibits autophagy (Pattingre et al.,
2005). Strong evidence for the importance of autophagy inhibi-
tion by these viral Bcl-2 homologs is provided by the MHV68
system. Mutating the Beclin binding domain of the MHV68 Bcl-
2 homolog did not effect the establishment of viral latency but
impaired the ability of the virus to maintain chronic infection in
mice (E et al., 2009).
Interestingly, the protein interacting with carboxy terminal
1 (PICT-1), a putative human tumor suppressor protein of
unknown function, has recently been shown to bind KSHV Bcl-2
(Kalt et al., 2011). Ectopic expression of PICT-1, which con-
tains two nuclear localization sequences (NLS) and a nucleolar
localization signal, caused KSHV Bcl-2 to relocalize from its nor-
mal mitochondrial localization into nucleoli thereby inhibiting
its anti-apoptotic activity. The ability of PICT-1 to counteract
KSHV Bcl-2-mediated autophagy inhibition was not examined in
the paper. However, since Beclin-1 is almost entirely located in
the cytoplasm and acts in this compartment (Liang et al., 2001),
sequestration in the nucleus may well interfere with the ability
of KSHV Bcl-2 to inhibit autophagy. If this proves to be the
case then PICT-1 may represent the ﬁrst example of a cellular
countermeasure against viral inhibition of autophagy.
All of the herpesvirus autophagy inhibitory proteins described
thus far act by interacting with Beclin-1. KSHV has developed an
additional inhibitory mechanism, targeting a separate component
of the cellular autophagymachinery. The viral FLICE like inhibitor
protein (v-FLIP), a homolog of a cellular (c-FLIP), can inhibit both
apoptosis and autophagy (Lee et al., 2009). v-FLIP binds Atg3 pre-
venting it from processing LC3 thereby inhibiting autophagosome
formation. Overexpression of either c-FLIP or v-FLIP inhib-
ited cell death induced by rapamycin stimulation of autophagy
(Lee et al., 2009).
In contrast to the herpesviruses described above varicella-zoster
virus (VZV) is unable to inhibit autophagy. Indeed, autophagy is
rapidly activated following VZV infection with many autophago-
somes present in infected cells in vitro and in infected cells within
skin vesicles (Takahashi et al., 2009; Carpenter et al., 2011). Unlike
the other neurotropic alpha herpesviruses HSV-1 and HSV-2,
VZV lacks an ICP34.5 ortholog; VZV also lacks a viral Bcl-2
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homolog. The high level of autophagy present in VZV-infected
cells may be the cause of the low titers of this virus obtained
in vitro. It is interesting to note that an inability to inhibit
autophagy has not proved detrimental to VZV; almost everyone
is infected with the virus and in that regard it is a highly success-
ful pathogen. Indeed, it has been postulated that VZV-induced
autophagy may be beneﬁcial to the virus, prolonging the sur-
vival of infected cells by reducing endoplasmic reticulum stress
(Carpenter et al., 2011).
AUTOPHAGY AND THE ADAPTIVE IMMUNE RESPONSE
TO HERPESVIRUSES
Herpesviruses have evolved an arsenal of immune evasion mech-
anisms in order to establish life-long latent infection of immuno-
competent hosts (Horst et al., 2011). As well as playing a key role
in innate anti-viral immunity, autophagy is also important in
adaptive immunity and autophagy manipulation by herpesviruses
affects this arm of the immune response. In agreement with the
earlier work suggesting xenophagy could reduce HSV-1 neurovir-
ulence, strains of HSV-1 incapable of inhibiting autophagy (due
to deletion of the Beclin-1 binding domain of ICP34.5) caused
less disease following corneal infection of mice (Leib et al., 2009).
However, no disease decrease was observed for Rag1 knockout
mice that lack B and T cells suggesting that the protective effect
was mediated by adaptive, rather than innate, immunity. In accor-
dance with this result mice infected with the mutant virus had
higher virus-speciﬁc CD4+ T cell responses compared to animals
infectedwithwild-type virus.While autophagy can reduceHSV-1-
mediated disease the relative contributionsmade by the innate and
adaptive immune responses are currently unclear and may differ
depending upon the model system being used.
Viral inhibition of autophagy can potentially limit adaptive
immunity by acting at two key stages. First, autophagy within
virus-infected cells may be important for the generation of cross-
primed CD8+T cell responses by dendritic cells (DCs). Inhibiting
autophagy in inﬂuenza-infected cells reduced their ability to stim-
ulate inﬂuenza-speciﬁc CD8+ T cells in mice (Uhl et al., 2009).
Similar results have also been observed using a tumor antigen
model (Li et al., 2008). Second, autophagy provides a route for
antigens to enter antigen-processing pathways within pathogen-
infected cells, allowing them to be processed and presented to
antigen-speciﬁc T cells. Since the ﬁrst landmark observation that
autophagy can generate an MHC II epitope from a self anti-
gen (Brazil et al., 1997) several pathogen-encoded antigens have
been shown to be processed this way. These antigens include the
bacterial protein neomycin phosphotransferase (NeoR; Nimmer-
jahn et al., 2003), the mycobacterial antigen Ag85B (Jagannath
et al., 2009), and EBV nuclear antigen 1 (EBNA1), the ﬁrst exam-
ple of a viral protein processed by autophagy for recognition by
CD4+ T cells (Paludan et al., 2005). Autophagy can also gener-
ate MHC class I epitopes, the ﬁrst example being arising from
studies on HSV-1 infection of murine macrophages (English
et al., 2009). As expected, autophagy was inhibited in the HSV-
1-infected cells by ICP34.5. These infected cells also presented
an MHC class I restricted viral epitope generated using the clas-
sical proteasome-dependent pathway. However, at later stages
of infection higher levels of the epitope were generated and an
additional processing pathway was involved that was sensitive
to baﬁlomycin A and 3-methyladenine, inhibitors of the vacuo-
lar processing pathway and autophagy respectively. In addition
to normal double membrane autophagosomes, the HSV-infected
cells also contained unusual four layered membrane structures
originating from the nucleus that, based on the presence of LC3,
appear to be autophagosomes. These unusual nuclear-derived
autophagosomeswere not observed in cells treatedwith rapamycin
to stimulate autophagy nor cells infected with recombinant HSV-1
lacking ICP34.5. They may therefore represent a cellular response
to a combination of HSV-1 infection and ICP34.5-mediated
blockade of conventional autophagy. A second interesting obser-
vation from this work was that presentation of the viral MHC
class I epitope by cells infected with HSV-1 lacking ICP34.5
was also sensitive to baﬁlomycin A and therefore involved the
vacuolar pathway. As these cells lacked the four layered autophago-
somes this result may indicate that classical double membrane
autophagosomes also contribute to the generation of MHC class I
epitopes.
NUCLEAR SHELTER – ANOTHER STRATEGY TO
EVADE AUTOPHAGY
Upon establishing latent infection, the herpesvirus genome per-
sists as an episome within the nucleus. To ensure the viral genome
is replicated and segregated into daughter cells the gammaher-
pesviruses EBV and KSHV each express a genome maintenance
protein (EBNA1 and latency-associated nuclear antigen (LANA)
respectively). Deletion of EBNA1 decreased EBV growth trans-
formation 10,000-fold, clearly demonstrating the vital role of
such proteins (Humme et al., 2003). Although loss of EBNA1 can
be compensated by integration of the EBV genome into cellular
DNA, this is a very rare event, again highlighting the importance
of a correctly functioning genome maintenance protein for the
gammaherpesviruses.
The dependence on the continuous presence of genome main-
tenance proteins to ensure life-long viral persistence represents a
potentialAchiles’heel for these viruses. Logically, onewould there-
fore expect genome maintenance proteins to be well protected
from immunological surveillance. This is indeed the case. EBNA1
contains a large internal glycine/alanine repeat (GAr) domain
that decreases EBNA1 processing and presentation by the HLA
class I processing pathway via several complementary mechanisms
(Levitskaya et al., 1997; Tellam et al., 2008; Apcher et al., 2009).
The KSHV genome maintenance protein LANA also contains an
internal repeat domain, in this case consisting of acidic residues,
that similarly reduces this protein’s synthesis (Kwun et al., 2007)
and degradation (Zaldumbide et al., 2007). In contrast to short-
lived proteins, which are generally thought to be degraded by the
proteasome, long-lived proteins are thought to be degraded by
autophagy; measuring the degradation of long-lived proteins is
a classical method for measuring the autophagy activity of cells
(Klionsky et al., 2008). The genome maintenance proteins might
therefore be potential substrates for autophagic degradation. This
is indeed the case for EBNA1, which was the ﬁrst viral protein
identiﬁed as being degraded by autophagy (Paludan et al., 2005).
Furthermore, two different EBNA1-speciﬁc CD4+ T cell clones
were able to recognize EBV-transformed B lymphoblastoid cell
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lines (LCLs) in an autophagy dependant manner, demonstrating
that such degradation could expose EBNA1 to the immune system.
Remarkably, of all the EBV latent cycle proteins EBNA1 contains
the greatest number of MHCclass II epitopes andmost individuals
possess strong CD4+ T cell immunity against this protein (Munz
et al., 2000; Leen et al., 2001; Hislop et al., 2007). Taken together,
these observations appear paradoxical: how can EBV persist in
MHC class II positive B cells despite strong CD4+ T cell responses
speciﬁc for EBNA1, the protein critical for viral persistence?
In contrast to the observations described above, other research
groups using CD4+ T cell clones speciﬁc for other EBNA1 epi-
topes found these cells were unable to recognize LCLs (Khanna
et al., 1997; Mautner et al., 2004). In our laboratory, CD4+ T cell
clones speciﬁc for two epitopes could recognize LCLs express-
ing natural levels of the EBNA1 protein while clones speciﬁc for
a third epitope could not (Leung et al., 2010). The discordant
results reported by different laboratories may therefore reﬂect real
differences in the presentation of different epitopes from this pro-
tein. Although cell surface levels were low, control experiments
conﬁrmed that the two epitopes presented by LCLs were indeed
endogenously accessing the MHC II pathway. Interestingly, only
one epitope was autophagy-dependent, the other being processed
by another intracellular route that is currently under investigation.
Different epitopes from the same source protein being processed
by different routes has been observed previously for inﬂuenza
hemagglutinin (Sinnathamby and Eisenlohr, 2003). When EBNA1
was over-expressed as a nuclear protein, surface levels of the two
naturally presented epitopes increased slightly, but the process-
ing routes remained the same. However, expressing EBNA1 as
a cytoplasmic protein, through mutation of its NLS, resulted in
all three epitopes being processed by autophagy and presented
at high levels by cells. This striking result was a direct result of
EBNA1’s new cytoplasmic localization since addition of a heterol-
ogous NLS reversed the effect (Leung et al., 2010). While EBNA1
needs to be localized to the nucleus for its correct functioning
in the virus life cycle, nuclear localization clearly brings an addi-
tional beneﬁt, namely limiting EBNA1’s endogenous processing
by macroautophagy and presentation to CD4+ T cells. Poten-
tially “nuclear shelter” (Leung and Taylor, 2010) could also help
reduce CD8+ T cell presentation of EBNA1. Reducing protein
turnover may decrease the need for newly synthesized replace-
ment polypeptides that are the dominant source of MHC class 1
peptides from EBNA1 (Lee et al., 2004; Tellam et al., 2004; Voo
et al., 2004; Mackay et al., 2009).
Are other nuclear-localized proteins sheltered from macroau-
tophagy like EBNA1? Studies using non-viral proteins suggest this
may be the case. The huntingtin and ataxin-1 proteins each con-
tain a large poly-glutamine repeat that can cause these proteins
to aggregate in cells. Aggregates of huntingtin or ataxin-1 were
degraded by autophagy in the cytoplasm but not in the nucleus
(Iwata et al., 2005). A mutation in the NLS of a tumor antigen
causing it to relocalize out of the nucleus enhanced its CD4+
T cell recognition (Wang et al., 1999). Although it is not known
if this epitope was processed by autophagy, the observation is
consistent with the EBNA1 data. In contrast to these examples,
presentation of an autophagy-dependant epitope from the NeoR
protein was not reduced by the addition of a heterologous NLS
(Riedel et al., 2008). The reason for this different result is unclear,
but one possibility is that it might reﬂect different rates of nuclear
import. Previous work has shown that although the addition of a
minimal NLS allows nuclear import, this occurs with slow kinet-
ics unless additional ﬂanking sequences are included (Rihs and
Peters, 1989). The import rate of the NLS-containing NeoR pro-
tein has not been measured, however EBNA1 is rapidly imported
following its translation suggesting that levels of cytoplasmic
EBNA1 are likely to be very low (Kitamura et al., 2006). Finally,
it is important to note that other endogenous MHC class II
processing pathways exist. Some of these pathways involve the
proteasome (Delmas et al., 2005; Tewari et al., 2005), others CMA
(Zhou et al., 2005) while others have not been mechanistically
deﬁned. Antigen localization can affect processing by one of these
alternative pathways. The CMV nuclear protein IE1 contains an
MHC class II epitope that is not processed by autophagy but
by a proteasome-dependent mechanism. Although relocalization
of IE1 into the cytoplasm did not alter the degree of presenta-
tion of this epitope, the mechanism of presentation was altered
(Delmas et al., 2005).
HOW DO NUCLEAR-LOCALIZED ANTIGENS ENTER THE
AUTOPHAGY PATHWAY?
The fact that some EBNA1 MHC class II epitopes are autophagy-
dependent raises the interesting question of where in the cell
does the nuclear-localized protein access the autophagic pathway?
Can autophagy occur in the nucleus? The best-studied example
of “nucleophagy” is Piecemeal Microautophagy of the Nucleus
(PMN), a form of microautophagy that occurs in yeast (Roberts
et al., 2003). During PMN, small pieces of the nucleus are pinched
off into the yeast degradative vacuole; PMN is therefore a rel-
atively gentle and selective process that can be tolerated by the
cell. A much more dramatic example of nucleophagy has been
observed in the ﬁlamentous fungusAspergillus oryzae. Here, entire
nuclei are degraded after being surrounded by large (1–2 μm
diameter) autophagosomes (Shoji et al., 2010). While such dras-
tic loss of genetic material would be lethal for any mononuclear
cell, it can be tolerated within the multi-nucleated hyphae of this
organism. Since autophagy is important for the growth of this
fungus under starvation conditions, nucleophagy may be acting
to recycle the constituents of redundant nuclei for use at growing
hyphal tips.
Do mammalian cells undergo nucleophagy? The extent to
which PMN takes place in other species is unknown, but homologs
of the yeast genes essential for PMN, Vac8, and Nvj1, have not
been identiﬁed in animal cells (Mijaljica et al., 2010). Granting
non-speciﬁc macroautophagy access to the nucleus could result
in irreversible loss of genetic material with catastrophic conse-
quences for the cell. Indeed, to guard against such loss mammalian
cells inhibit autophagy during mitosis, a time when chromo-
somes enter the cytoplasm following breakdown of the nuclear
membrane (Eskelinen et al., 2002). However, nucleophagy has
been observed in mammalian cells in select circumstances. In
mouse macrophages HSV-1 infection triggers an unusual form of
autophagy involving four-layer autophagosomes emerging from
the nuclear envelope (English et al., 2009). It is not known
whether these unusual autophagosomes can form in human cells
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infected with HSV-1, or if other herpesviruses can trigger their
formation.
Other examples of nucleophagy occur in the context of genetic
mutations. In Bloom’s syndrome, a rare cancer-predisposing dis-
order caused by mutation of the BLM gene, micronuclei bud
from the nucleus into the cytoplasm (Yankiwski et al., 2000). The
extent to which these cytoplasmic micronuclei are substrates of
autophagy and the ability of normal cells to release micronuclei
are currently not known. Finally, cells with fragile nuclei, caused by
mutations in genes encoding nuclear lamina proteins, have been
observed to contain perinuclear autophagosomes/autolysosomes-
containing nuclear components (Park et al., 2009). Intriguingly,
the authors report similar autophagosomes/autolysosomes in
wild-type cells, although at a much lower frequency.
Autophagy is now known to exhibit greater selectivity for its
substrates than once thought. Several autophagy adaptor pro-
teins have now been shown to transport a range of substrates
to autophagosomes for degradation. These substrates include
aggregated or ubiquitinated proteins, damaged mitochondria, and
intracellular bacteria (reviewed in Johansen and Lamark, 2011).
Selective autophagy could be another route for nuclear proteins to
enter cytoplasmic autophagosomes, one that could operate with-
out causing genetic loss. One of the autophagy adaptor proteins,
p62 (also called SQSTM1), has recently been shown to deliver cap-
sids of Sindbis virus to autophagosomes (Orvedahl et al., 2010).
With respect to the selective autophagy of nuclear proteins, p62
is of particular interest since it contains both nuclear localiza-
tion and nuclear export sequences and consequently shuttles
rapidly between the nucleus and cytoplasm (Pankiv et al., 2010).
However, it is not yet known whether p62 is involved in the
selective degradation of nuclear proteins by autophagy.
ACTIVATION OF AUTOPHAGY BY HERPESVIRUSES
Thus far we have considered autophagy as a threat to her-
pesviruses. However, the relationship between herpesviruses
and autophagy is more complex and several examples exist of
herpesviruses activating autophagy at different stages in their life-
cycle. Autophagy activation can occur during lytic infection. As
described earlier autophagy is rapidly activated in VZV-infected
cells because the virus apparently lacks mechanisms to inhibit this
pathway. However, autophagy activation has also been reported
for viruses that do possess such mechanisms, suggesting that
autophagy may be beneﬁcial for viruses at particular stages of
their replicative cycle. Although HSV-1 encodes the autophagy
inhibitor ICP34.5 this virus has been reported to rapidly acti-
vate autophagy in human fetal foreskin ﬁbroblasts (McFarlane
et al., 2011). Autophagy induction by HSV-1 has also been
reported in murine macrophages, although in this case classical
macroautophagy still appeared to be inhibited by virus-encoded
ICP34.5 and a morphologically distinct type of macroautophagy
was observed (English et al., 2009). CMV infection also rapidly
activates autophagy that is subsequently inhibited by the CMV-
encoded protein TRS1 (McFarlane et al., 2011; Chaumorcel et al.,
2012). KSHV also appears to activate autophagy during lytic reac-
tivation. The KSHV protein RTA is able to activate autophagy,
inhibiting this process reduced RTA-mediated lytic gene expres-
sion and KSHV replication suggesting autophagy plays a key role
in the replication of KSHV during lytic cycle (Wen et al., 2010).
Autophagy activation can also occur during herpesvirus latency.
The EBV-encoded latent membrane protein 1 (LMP1) induces
autophagy in EBV transformed B cells (Lee and Sugden, 2008).
This induction does not result from LMP1’s well-documented
activation of cellular signaling pathways but from the presence
of three of the molecule’s transmembrane spanning domains.
Since LMP1 is also degraded by autophagy these domains, which
had previously not been assigned a functional role, may provide
LMP1 with a feedback mechanism that regulates cellular levels of
the protein.
CONCLUSION
During their evolution, the herpesviruses have developed a range
of mechanisms to interact with the host autophagy machinery.
Under some circumstances these viruses need to evade host immu-
nity and this is achieved in several ways. One way is to target
key cellular proteins required for autophagy. In this regard, sev-
eral viruses have independently evolved mechanisms that target
Beclin-1, reﬂecting the key role this protein plays in autophagy.
The targeting of another autophagy protein, ATG3, by KSHV
raises the possibility that a range of inhibitory mechanisms exist,
waiting to be discovered. Another way to evade immunity may
be through localization of genome maintenance proteins into the
nucleus, therebyminimizing their access to the autophagymachin-
ery. In this review, we have focused on macroautophagy, which is
the best characterized of the three currently deﬁned autophagy
pathways. The other pathways are beginning to be elucidated
and one of them, CMA, has been shown to generate an MHC
class II restricted epitope from a non-viral antigen (Zhou et al.,
2005). However, the contribution of these other pathways to viral
immunity, and whether they too are inhibited by herpesviruses,
is currently unknown. Finally, a complex balance exists between
herpesviruses and autophagy within the host cell and under
some circumstances herpesviruses activate autophagy, presum-
ably for their beneﬁt. Two recent observations – PICT-1-mediated
relocalization of KSHV Bcl-2 away from its site of action, and
nuclear-derived autophagosomes in mouse macrophages infected
with HSV-1 – raise the possibility that cells possess mechanisms
to counteract viral manipulation of autophagy. Understanding
the balance between autophagy inhibition and activation within
virally infected cells, and the consequences for anti-viral immunity,
presents a challenge and an opportunity for future research.
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